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Abstract: Prediction of prostate cancer in primary care is typically based upon serum total
prostate-specific antigen (tPSA) and digital rectal examination results. However, these tests
lack sensitivity and specificity, leading to over-diagnosis of disease and unnecessary, invasive
biopsies. Therefore, there is a clinical need for diagnostic tests that can differentiate between
benign conditions and early-stage malignant disease in the prostate. In this review, we
evaluate research papers published from 2009 to 2019 reporting biomarkers that identified
or differentiated benign prostatic hyperplasia (BPH) from prostate cancer. Our review
identifies hundreds of potential biomarkers in urine, serum, tissue, and semen proposed as
useful targets for differentiating between prostate cancer and BPH patients. However, it is
still not apparent which of these candidate biomarkers are most useful, and many will not
progress beyond the discovery stage unless they are properly validated for clinical practice.
We conclude that this validation will come through the use of multivariate panels which can
assess the value of biomarker candidates in combination with clinical parameters as part of
a risk prediction calculator. Implementation of such a model will help clinicians stratify
patients with prostate cancer symptoms in primary care, with tangible benefits for both the
patient and the health service.
Keywords: prostate cancer, benign prostatic hyperplasia, biomarkers, differentiation,
transrectal ultrasound-guided biopsy
Introduction
Serum prostate-specific antigen (PSA) was deemed a viable tumor marker for the
detection of prostate cancer (PCa) allowing clinicians to track patient response to
cancer treatment.1 However, initial investigations into PCa usually involve
a combination of digital rectal examination (DRE) and measurement of PSA levels.
Based on these measurements a referral for Transrectal Ultrasound (TRUS)-guided
biopsy may be made. Whilst PSA has helped identify many more patients with PCa,
one of the main obstacles for clinicians is to differentiate PCa from non-malignant
conditions. One of these conditions, benign prostatic hyperplasia (BPH), can also
present with raised levels of PSA. With no universally agreed way to stratify
suspected cases of PCa to help inform diagnostic process at this point, many men
undergo unnecessary biopsy or further procedures that they may not require.2
It is therefore clear that there is a need for more accurate methods to risk stratify
men who present with symptoms of PCa, to prevent the over-diagnosis and unneces-
sary treatment of patients with benign conditions.3 Successfully implemented in
Correspondence: Declan J McKenna
Tel +44 2870124356
Email dj.mckenna@ulster.ac.uk
Cancer Management and Research Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Cancer Management and Research 2020:12 5225–5241 5225
http://doi.org/10.2147/CMAR.S250829
DovePress © 2020 McNally et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
 
Ca
nc
er
 M
an
ag
em
en
t a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
86
.1
29
.2
14
.4
0 
on
 2
7-
Ju
l-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
primary care, this would greatly reduce the over-diagnosis
rates of patients, as well as relieving financial and manage-
ment pressures on healthcare providers. Recent research
efforts suggest that this stratification is likely to be based on
the identification of reliable biomarkers which can improve
on the current use of PSA measurement to diagnose PCa.
This review aims to present and evaluate data from studies
published over the past decade that have proposed biomar-
kers which may be useful for differentiating between BPH
and PCa.
BPH is a non-malignant enlargement of the prostate
caused by cellular hyperplasia that occurs within the tran-
sitional zone.3 BPH is associated with age, with around
50% of men aged 50, 70% of men aged 70, and 90% of
men aged 80 being affected.4,5 The proliferation of pro-
static cells leads to an increase in the size of the prostate
as well as urethral obstruction and lower urinary tract
infections (LUTS). Risk factors for BPH include age,
decreased testicular function, metabolic syndrome, family
history of BPH and obesity.4 Several studies have inves-
tigated an association between BPH and PCa, although the
underlying pathophysiology between the two conditions
remains unclear.6–8 A meta-analysis of 19 studies invol-
ving 15,899 patients determined that BPH was associated
with an increased risk of PCa, risk ratio (RR) 2.93, (95%
CI=1.88–4.56), P < 0.0000.9 The authors demonstrated
that the association between BPH and PCa was stronger
within Asian populations when compared to Caucasians;
RR 6.09 and 1.54, respectively. The authors also sug-
gested that hormones, inflammation, and metabolic syn-
drome likely play a role in the pathophysiology of BPH.9
There is also evidence that the homeostasis between pros-
tate cell proliferation and cell death supported by dihy-
drotestosterone (DHT) and estrogen is often disrupted in
BPH patients.10 Additionally, aggressive BPH is asso-
ciated with an elevated risk of developing PCa and the
subsequent cancer can be high grade compared to indivi-
duals without fast-growing BPH.11 Although the majority
of findings are hypothesis-generating rather than hypoth-
esis-confirming, the evidence does support the theory that
BPH is a risk factor involved in the pathogenesis of
PCa.12–14
However, despite this evidence, it is not inevitable that
BPH will progress to PCa in any given individual.
Therefore, it is important to be able to distinguish BPH
patients at an early stage to prevent further invasive and
unnecessary tests in these individuals. PSA testing alone is
not able to make this differentiation, so new biomarkers
are required to improve the risk-stratification of patients at
this stage.
Prostate Specific Antigen
Currently, PSA is one of the most widely used biomarkers
for the detection and management of PCa. Prior to PSA
measurement, PCa was mainly predicted by DRE.
However, DRE as a diagnostic tool has low sensitivity
and specificity, as well as user subjectivity between clin-
icians performing the examination.15 PSA testing was
a clear diagnostic improvement and was introduced in
the United States in 1987 to determine if patients were
responding to curative therapy. Soon after, PSA was used
for screening patients at risk of PCa, leading to an increase
in disease detection and a decline in mortality.16 PSA is
a kallikrein-like serine protease produced by the epithelial
cells of the prostate to help liquefy ejaculate and aid sperm
motility. Extraprostatic production of PSA is provided
mainly by the periurethral glands, which in turn leads to
measurable levels of PSA in the serum17 The San Diego-
based company Hybritech Inc. was the first company to
propose a serum PSA threshold of 4.0 ng/mL after a study
on healthy men.17 Subsequently, a PSA value of >4.0 ng/
mL became the industry standard for recommending
a prostate biopsy. Since the introduction of this threshold,
studies have shown that PSA testing has a sensitivity of
67–80% and has helped diagnose a large number of
patients with PCa since it was first introduced.17
However, although PSA is organ-specific, it is not
a cancer-specific biomarker. BPH and other conditions, for
example, prostatitis, inflammation of the prostate, can raise
serum PSA levels. Conversely, PCa has been shown in males
who present with normal PSA levels.16 Hence, there is a lack
of specificity with PSA which can lead to over-diagnosis of
PCa and unnecessary treatment. Data gathered from the
Surveillance, Epidemiological and End Results (SEER) reg-
istry estimates that screening for PCa using PSA has resulted
in 28% of over-diagnosed cases in the USA.18 Likewise, the
European Randomised Study of Screening for Prostate
Cancer (ERSPC) trial estimated that using PSA as
a screening tool for PCa led to 50% of patients being over-
diagnosed.19 Actively diagnosing a clinically insignificant
tumor can lead to unnecessary treatment, such as radical
prostatectomy or radiotherapy. To avoid this, healthcare pro-
viders are utilizing the strategy of active surveillance, where
regular PSA and DRE testing is used alongside biopsies over
a period of time to minimize the risk of over-diagnosis.
However, regular check-ups and repeated prostate biopsies
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are invasive and can be very painful for the patient. This
unsurprisingly can cause high levels of anxiety and stress and
may discourage the patient to seek medical attention at all.16
It is known that serum PSA levels increase with age.
This is most likely due to the contribution of an enlarged
prostate associated with old age as well as the decreased
retention of the prostatic epithelium. Age-specific PSA has
been shown to increase the detection of PCa in younger
men (50–59 years) by 15% but also shown to increase the
number of biopsies performed by 45%.20 To address these
issues, various studies have investigated more nuanced
measurements of PSA expression to help improve its use-
fulness for PCa diagnosis. Significant research has been
performed on free PSA, rather than total PSA (tPSA),
demonstrating the ratios of free-to-total PSA in serum
may improve the diagnostic specificity by 15–20%.21
This type of test is recommended for patients who present
with PSA levels within the “grey-zone” of 4.0 to 10.0 ng/
mL. Initially, it was proposed that high levels of free PSA
were associated with benign prostate tissue and
a decreased probability of PCa.21 However, this test was
not widely implemented as a screening tool due to incon-
sistencies in later studies.17 The [−2] isoform of proPSA
has emerged as a promising biomarker due to its ability to
differentiate between PCa and BPH, where levels appear
raised in PCa. One large prospective study of patients with
PCa showed that the percentage of [−2] proPSA improved
the specificity to 44.9% in comparison to total and free
PSA which was 30.8% and 34.6% respectively whilst also
achieving a sensitivity of 80% for detecting PCa.22
The Prostate Health Index (PHI) can also be considered
a biomarker, calculated using the following formula: PHI=
([−2]proPSA/freePSA)×√PSA. In one study, both the [−2]
proPSA (AUC = 0.76) and the PHI test (AUC = 0.77) out-
performed the tPSA test when used to detect PCa between
the ranges of 2.5–10 ng/mL.23 These studies have shown
the predictive superiority of these two tests compared to
that of just tPSA based screening alongside a significant
improvement in accuracy. However, other studies do not
agree with these results and indicated that when the goal is
to detect at least 95% of the aggressive tumors, PHI does
not seem to be much more effective than the %free PSA
and the PSA density.24
PSA density is calculated as the tPSA in ng/mL
divided by prostate volume (mL). Nordström et al in
2018 suggested that PSA density might inform clinicians
more on biopsy decisions after determining that a cut-off
of 0.10 ng/mL2 resulted in a detection rate of 77% of
Gleason score ≥7 tumors compared to tPSA alone, 64%
(n = 947).25 Additionally, both Verma et al in 2014 and
Sebastianelli et al in 2019 both suggested that PSA density
could be used to reduce unnecessary biopsies after deter-
mining the marker was significant for the detection of
aggressive PCa.26,27 However, Liu et al in 2015 concluded
in their paper that if a patient has PSA levels of <2.0 ng/
mL, PSA density does not differentiate the PCa effectively
enough (n = 343).28
PSA velocity is the measure of the rate of PSA increase
over time. Serum PSA velocity increases significantly in
the presence of a prostate tumor compared to that of
a benign disease alone. However, no evidence was found
to support the recommendation that men with high PSA
velocity should be biopsied in the absence of other
indications.29
Despite these varied approaches to PSA measurement,
there are still many limitations to current PSA testing for
PCa. The PSA test possesses a negative benefit-to-harm
ratio based on population-based estimates.16 The future of
individualized PSA-based screening seems to lie as
a component of multivariate risk stratification, carried out
by using various nomograms and prediction risk tools.16
Therefore, the current challenge is to identify other bio-
markers that can be used in combination with PSA in
primary care to differentiate BPH from PCa.
Transrectal Ultrasound-Guided Biopsy
Grey-scale TRUS-guided biopsy is the gold standard for pros-
tate imaging and is essential for achieving a histological diag-
nosis of a prostatic carcinoma through a guided biopsy.30 The
TRUS-guided biopsy is also the main procedure recom-
mended by the National Institute for Health and Care
Excellence (NICE) guidelines to diagnose PCa.31 Although
the procedure is considered safe, the number of post-biopsy
complications are on the rise, and often reported in up to 50%
of cases. Complications include pain, haematuria, haematos-
permia, urinary retention as well as infection.32 The pain
reported from a TRUS-guided biopsy is relative to the number
of cores removed.33 In a study performed on patients after
a sextant biopsy (six-core removal), 94% of patients found the
procedure painful and 24% of patients reported the pain as
moderate to severe. The extended 12-core biopsy can result
in higher levels of pain, subsequent inadequate sampling and
eventual abandonment of the procedure.33 Many patients have
refused when asked if they would undergo a repeat prostate
biopsy. Pain is subjective, it is difficult to quantify. However, it
is clear that both psychosocial factors and physical attributes
Dovepress McNally et al
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play an important role when patients require a prostate
biopsy.34 Aside from immediate surgical pain, complications
and infection can occur. UTIs were reported at an occurrence
rate of 6% post-TRUS biopsy, with 30–50% of patients within
that 6% going on to develop bacteremia. Approximately 0.1%
- 2.2% of TRUS biopsy patients will develop severe sepsis.35
One study reported that 1 in 4 post-TRUS biopsy patients
hospitalized due to E. coli bacteremia had severe sepsis that
required them to be admitted to the intensive care unit (ICU).32
Interestingly, there are reports to suggest that the rate of
infectious complications after TRUS biopsy is on the rise.
A study based in Ontario, Canada reported an increase in the
rate of hospitalization within 30 days following a TRUS
biopsy, from 1.0% of patients in 1996 to 4.1% in 2005 (P <
0.0001).36
Although the frequency of complications is relatively
low, the problem is still a substantial one, given the number
of biopsies performed and the associated economic burden
from treating biopsy-related complications.32 A new test that
has high specificity and could confidently stratify patients
into groups that require a biopsy and those who could be
stratified to watch and wait, would significantly reduce the
number of post-TRUS biopsy complications.
The rapidly growing use of multiparametric magnetic
resonance imaging (mp-MRI) offers a much safer alternative
to the TRUS-guided biopsy. The use of MRI continues to
show increased accuracy for the detection, localization, risk
stratification and staging of PCa for patients.37–40 The largest
benefit will come from the reduced number of unnecessary
biopsies being performed, which in turn will significantly
reduce levels of overdiagnosis within patients displaying
signs of PCa.41 However, although mp-MRI has shown pro-
mising results, it is still not perfect. There is a risk that 5–20%
of index lesions are missed. However, in combination with
standard TRUS-guided biopsy, this can be improved.42–44
Additionally, currentMRI technology also lacks the resolution
to detect tumors with a smaller volume and a lower Gleason
score, making it less reliable at detection early-stage PCa.43,44
Nevertheless, the benefits of mp-MRI are clear and offer an
attractive alternative to TRUS-guided biopsies, although
access to the required instrumentation and resources may
still be a clinical barrier to widespread implementation.
The Search for New Biomarkers
The most ideal biomarkers are ones that can be measured
accurately and reproducibly in a minimally invasive
manner.45 Biomarkers can be measured in tissue, blood,
urine and/or semen, but standardized collection and
analysis of these samples can present some unique chal-
lenges. As a result, there is no consensus on the best
samples to use, or the optimal biomarkers to measure
once the sample has been collected. This review aims to
provide a comprehensive overview of research being per-
formed that purport to identify genomic and/or proteomic
biomarkers that can differentiate between BPH and PCa.
The following search criteria were employed:
● Article obtained using either PubMed or Google
Scholar
● Manuscripts published within the last 10 years
● Articles are in English
● Biomarkers must be analyzed from either blood,
urine, tissue or seminal fluid
● Analyzed specifically and separately both PCa and
BPH specimens in the study
● Attempted to differentiate between PCa and BPH
Using this filtered approach, we retrieved 104 published
papers for blood and urine-based biomarkers. Their find-
ings are reported in Tables 1–4, with similar data for tissue
and seminal fluid biomarkers gathered from 49 published
papers presented in Supplementary Tables 1-3.
Blood-Based Biomarkers
Genomic Blood Biomarkers
Table 1 provides a list of blood-based biomarkers from 19
papers that have been investigated by researchers using
genomic techniques to identify patterns that could poten-
tially differentiate BPH and PCa.
Proteomic Blood Biomarkers
Table 2 provides a list of blood-based biomarkers from 44
papers that have been investigated by researchers using
proteomic techniques to identify patterns that could poten-
tially differentiate BPH and PCa.
Urine-Based Biomarkers
Genomic Urine Biomarkers
Table 3 provides a list of urine-based biomarkers from 21
papers that have been investigated by researchers using
genomic techniques to identify patterns that could poten-
tially differentiate BPH and PCa.
Proteomic Urine Biomarkers
Table 4 provides a list of urine-based biomarkers from 23
papers that have been investigated by researchers using
McNally et al Dovepress
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Table 1 Blood-Based Biomarkers Derived from Genomic Techniques
Biomarkers BPH
(n)
PCa
(n)
Method All Significant
(p<0.05)
Reference
miR-15a↓, 35 35 RT-PCR Yes 46
miR-126↓,
miR-192↓, miR-377↓
miR-18a↑ 24 24 RT-PCR Yes 47
let-7c↓, let-7e↓, 60 64 qPCR Yes 48
let-7i↓,
miR-26a-5p↓,
miR-26b-5p↓,
miR-18b-5p↓,
miR-25-3p↓
Retinoic Acid Receptor β2 (RARβ2) ↑ 94 91 qPCR Yes 49
Cell-Free DNA↑ 112 96 qPCR Yes 50
let-7a↑, miR-210↑, miR-562↑, miR-616↑ 13 31 RT-PCR Yes 51
let-7c↓, miR-30c↓, 16 59 qPCR Yes 52
mirR-141↓,
miR-375↓
miR-708↓, 39 76 qPCR Yes 53
miR-221↓,
miR-518d-5p↓,
miR-675↑,
miR-1180↑,
miR-1225-5p↑,
miR-659↑
miR-26a↑, 18 37 qPCR Yes 54
miR-195↑, let7i↑
Glutathione S-Transferase Pi 1 (GSTP1)↑ 34 31 MS-PCR Yes 55
miR-499, 353 355 PCR-RFLP Yes 56
miR-196a2,
miR-27a variants
Growth Arrest and DNA Damage Inducible Alpha (GADD45a) Methylation↑ 48 34 PyroSequencing Yes 57
Glutathione S-Transferase Pi 1 (GSTP1)↑, Ras Association Domain Family 1 Isoform
A (RASSF1A)↑
103 83 MS-PCR Yes 58
Cell-Free DNA↑ 76 50 Spectrophotometry Yes 59
miR-375↑ 35 146 qPCR Yes 60
(Continued)
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proteomic techniques to identify patterns that could poten-
tially differentiate BPH and PCa.
Tissue- and Semen-Based Biomarkers
Supplementary Tables 1 and 2 provide a list of tissue-
based genomic and proteomic biomarkers, respectively,
retrieved from 46 published papers, which are proposed
as differentiating between BPH and PCa.
Supplementary Table 3 provides a list of biomarkers
from seminal fluid retrieved from 3 published papers which
are proposed as differentiating between BPH and PCa.
Discussion
The data presented demonstrate clear global research inter-
est in finding biomarkers that can differentiate between
PCa and BPH. It is also notable that major advances in
both genomic and proteomic technologies have helped
facilitate the identification and analysis of many novel
biomarkers. The challenge now is to determine which
biomarkers, or combination of biomarkers, provides the
most effective way to risk stratify PCa patients in primary
care. This will require careful, robust analysis to ensure
the most useful candidates are selected.
It is interesting to note that the majority of biomar-
kers listed are all different, with very little overlap
between different groups investigating the same biomar-
kers. One set of biomarkers that did receive attention
from multiple groups were PSA glycoforms, again
emphasizing the importance of PSA-related measure-
ments for an accurate diagnosis. This is an umbrella
term reflecting the various glycosylation profiles that
PSA can possess, yet very few of the same PSA glyco-
forms were investigated by separate groups. The inves-
tigators used carbohydrate-binding proteins called lectins
to detect these glycolytic changes in an immunoassay
format.152 All of the groups investigating various PSA
glycoforms reported successful results in some form in
both serum and urine. However, within other cancers,
lectins typically only detected late-stage malignancies
and a select few of the papers referenced here that
reported noteworthy results did not supply the Gleason
score. Hence, PSA-related measurements remain likely
to be an important factor for PCa prediction and biopsy
referral, but the information contained in the tables
demonstrate that many other candidate biomarkers offer
clear potential for improving PCa diagnosis, prognosis,
and management. For example, Filamin-A and Filamin-
B are mentioned in our tables but are also well cited as
significant contributors to the differentiation of PCa from
non-cancer patients. The two proteins play a major role
in cell migration, vascular development, extracellular
signaling and activity of integrins.95,153 Filamin-A and
androgen receptor (AR) association play a role in nerve
growth factor (NGF) induced cell migration where it is
known PCa is associated with the synthesis of large
amounts of NGF which then stimulates tyrosine receptor
kinase A (TrkA).154 This is just one example of potential
successful PCa biomarkers that have the possibility of
identifying cancer quicker or preventing overdiagnosis
within patients.
However, lack of follow-up in terms of validation and
clinical trials means many of these candidate biomarkers
will not progress beyond the discovery stage. Research
efforts need to be improved in terms of validating these
candidate biomarkers within larger cohorts to translate the
findings to clinical practice.155 Moreover, the implementa-
tion of improved risk stratification approaches for PCa
Table 1 (Continued).
Biomarkers BPH
(n)
PCa
(n)
Method All Significant
(p<0.05)
Reference
miR-410-5p↑ 121 149 qPCR Yes 61
SAP30L Antisense RNA 1 (SAP30L-AS1)↓, SWI/SNF Complex Antagonist Associated
With Prostate Cancer 1 (SChLAP1)↑
46 34 qPCR Yes 62
MD-miniRNA↑ 32 63 qPCR Yes 63
miR-15a↓, miR-16-1↓ 70 70 qPCR Yes 64
Note: ↓/↑: Expression levels in PCa group compared to that of BPH group.
Abbreviations: miRNA, microRNA, Let-7, lethal-7 gene family, RT-PCR, reverse transcription-polymerase chain reaction, qPCR, quantitative polymerase chain reaction,
MS-PCR, methylation specific-polymerase chain reaction, PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.
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Table 2 Blood-Based Biomarkers Derived from Proteomic Techniques
Biomarkers BPH
(n)
PCa
(n)
Method All
Significant
(p<0.05)
Reference
Total Cholesterol↑, Triglycerides↑ 40 40 Atomic Absorption
Spectrophotometry
Yes 65
Free to Total PSA Ratio↓ 283 49 Immunoassay Yes 66
Pigment Epithelium-Derived Factor (PEDF) ↓, Zinc-α2-Glycoprotein
(ZAG)
13 37 2D-DIGE, MS, WB, ELISA,
IHC
No 67
Glutathione peroxidase 3 (GPx-3)↓, Apolipoprotein A-IV (ApoA-IV)
↓, ApoA-I↓, Coagulation Factor XIII B Chain↑, Antithrombin-III↓, α-
1-Antitrypsin↓, α-2-Macroglobin↓, Thrombin↓, Kininogen-1↑
14 32 2D-DIGE, MS, NMR,
Gene Ontology
Enrichment Analysis
Yes 68
Matrix Metalloproteinase-26 (MMP26)↑ 40 80 ELISA Yes 69
Cyclin B1↑ 21 174 ELISA, WB Yes 70
Prostate Health Index (PHI)↑, α2,3-Sialylated PSA↑ 29 50 Glycosylation
Immunoassay
Yes 71
Human Growth Factor (HGF)↑, Vascular Endothelial Growth Factor
(VEGF)↑, Omentin↑, Leptin↑
40 40 ELISA Yes 72
Prostate Health Index (PHI)↑ 150 113 Immunoassay Yes 73
α1,2-Fucosylated PSA↑ and β-N-Acetylgalactosaminylated PSA↑ 20 20 Lectin Column
Chromatography, ELISA
Yes 74
Estradiol↑, Insulin↓, Insulin Growth Factor 1 (IGF-1)↓ 70 70 Immunoassay Yes 75
β-N-Acetylgalactosaminylated PSA↑ 184 244 Immunoassay Yes 76
Apolipoprotein A2 (APOA2)↓, Complement C3 Chain Fragment
(C3f)↓, Inter-Alpha-Trypsin Inhibitor Heavy Chain
8 8 2DE SS, WB, LA
Chromatography, MS
Yes 77
4 Fragment (ITIH4f)↓, alpha-1-Antitrypsin (AAT)↑, High Molecular
Weight Kininogen (KNG)↑, Transthyretin (TTR)↑
tPSA↑, Carbonic 120 100 Piezoelectric Assay Yes 78
Anhydrase 1 (CA1)↑, IL-6 Soluble Receptor (IL-6sR)↓, Spondin-2↓
Platelet to Lymphocyte Ratio↑ 110 76 Cell Count No 79
Prolidase, Malondialdehyde, Superoxide Dismutase 51 30 Spectrophotometry No 80
60S Ribosomal Protein L7 Clones↑ 70 49 Protein Macroarrays Yes 81
Glypican-1↓ 15 15 ELISA, FC, WB Yes 82
f/tPSA Ratio↓, α2,3-Sialylated PSA↑, Cathepsin D↑ 100 75 ELISA Yes 83
Secreted group IIA phospholipase A2 (sPLA2-IIA), C-reactive
protein (CRP)
25 25 ELISA No 84
Serum Amyloid A (SAA), Secreted Group IIA Phospholipase A2
(sPLA2-IIA), C-Reactive Protein (CRP)
55 55 Immunoassay No 85
sPSP94/tPSA Ratio↑ 44 33 ELISA Yes 86
(Continued)
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Table 2 (Continued).
Biomarkers BPH
(n)
PCa
(n)
Method All
Significant
(p<0.05)
Reference
α2,3-Sialylated PSA↑ 35 35 Lectin Column
Chromatography, ELLA
Yes 87
α1,2 Fucosylated PSA↑ 13 13 ELLA Yes 88
Dihydrotestosterone (DHT)↓ 97 60 LC-MS/MS, IHC Yes 89
TAR DNA-Binding Protein (TARDBP)↑, Talin-1↑, PARK7↑, The
Lentiviral Integrase Binding Protein (LEDGF)↑, Caldesmon-1
(CALD1)↑
39 41 Microarrays Yes 90
Alcohol Dehydrogenase Isoenzyme II (ADH II)↓ 34 52 Spectrophotometry Yes 91
Cluster of differentiation 40 (CD40L)↓ 15 15 ELISA Yes 92
Mac-2 Binding Protein (Mac-2BP) 50 50 ELISA No 93
Serum Insulin-Like Growth Factor 1, Insulin-Like Growth Factor
Binding Protein 3 (IGF1, IGFBP3)
113 36 ELISA,
Radioimmunoassays
No 94
Filamin A, Filamin B, Keratin-19 (FLNA, FLNB and KRT19) 122 311 ELISA Yes 95
Fibronectin 1↑, Afamin↑, α-2-HS-Glycoprotein Chain B,
Ceruloplasmin↑, β-2-glycoprotein 1↑
5 5 iTRAQ, IHC, WB, MS Yes 96
PSA 2-DE Subform F3↓ 20 20 ELISA,
Immunoadsorption, 2-DE,
Immunodetection
Yes 97
Prostate Specific Antigen (PSA)↑, Prostatic Acid Phosphatase (PAP)↓ 30 24 ELISA, Kinetic Method Yes 98
Vascular Endothelial Growth Factor (VEGF)↑ 57 44 ELISA Yes 99
tPSA↑, Mean Platelet Volume↓, and Platelet Distribution Width↑ 108 100 Immunoassay, Flux
Cytometry
Yes 100
Fetuin ↑ - - Nanoelectrode Label Free
Detection
Yes 101
Omentin↑, Blood Urea Nitrogen↑, Creatinine↑, Total Cholesterol
(TC)↑, Low-Density Lipoproteins (LDL)↑, tPSA↑
30 50 ELISA,
Spectrophotometry
Yes 102
tPSA↑, fPSA↑, f/tPSA Ratio↓, Ferritin↑, Triglycerides↑, Total
Cholesterol (TC)↑, Low-Density Lipoprotein (LDL)↑, Very Low-
Density Lipoprotein (VLDL(↑, Gamma-Glutamyltransferase (GGT)↑
951 2002 Immunoassay,
Spectrophotometry
Yes 104
Claudin 3↑ 69 15 MS Yes 105
Testosterone/Prostate-Specific Antigen ratio (T/PSA)↓ 92 164 Immunoassay Yes 106
Serum PF4V1↓, tPSA↑ 38 66 iTRAQ, IHC, WB, ELISA Yes 107
Thioredoxin Reductase (TR)↑ 100 120 ELISA Yes 108
Note: ↓/↑Expression levels in PCa group compared to that of BPH group.
Abbreviations: ELISA, enzyme-linked immunosorbent assay, WB, Western blot, ELLA, enzyme-linked lectin assay, MS, mass spectrometry, FC, flow cytometry, IHC,
immunohistochemistry, NMR, nuclear magnetic resonance, LC-MS, liquid chromatography-mass spectrometry, iTRAQ, Isobaric tag for relative and absolute quantitation.
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must be practically and financially feasible, using
approaches that return results in a timely manner.
The variety of biomarkers under investigation has
inevitably led to the development of several commer-
cially available prostate cancer tests that variously rely
upon protein and gene expression measurements in
biopsy, blood and urine samples.156 Each test utilizes
a selection of different biomarkers, such as PSA-related
measurements, expression of selected genes, the extent
of gene methylation or detection of PCa-related gene
fusions. Each test is positioned for clinical use in var-
ious cohorts of men at different stages of the disease
management process, either before or after biopsy or
following treatment. More tests are in development by
Table 3 Urine-Based Biomarkers Derived from Genomic Techniques
Biomarkers BPH
(n)
PCa
(n)
Method All
Significant
(p<0.05)
Reference
PRCAT17.3↑, PRCAT38↑ 19 19 qPCR Yes 109
let-7e↓, let-7c↓, miR-30c↓, miR-25↓, miR-346↑, miR-622↑, miR-940↑, miR1285↑ 17 25 qPCR Yes 110
PCA3↑ 26 22 qPCR Yes 111
RASSF1↑, GSTP1↑, RARB↑ 32 253 qPCR Yes 112
miR-222-3p↓, miR-24-3p↓, miR-30c-5p↑ 29 215 RT-PCR Yes 113
miR-222-3p↓, miR-24-3p↓, miR-30c-5p↑ 289 758 RT-PCR Yes 114
miR-21-5p↑, miR-141-3p↑, miR-205-5p↑ 22 23 qPCR Yes 115
miR-1825↑, miR-484↓ 12 8 WGS Yes 116
HIST1H4K 29 57 qPCR No 117
Prostate Cancer Antigen-3 (PCA3)↑ 40 24 qPCR Yes 118
UDP-N-Acetylglucosamine Pyrophosphorylase 1 (UAP1), PDZ and LIM Domain 5
(PDLIM5), Inosine Monophosphate Dehydrogenase 2 (IMPDH2), Heat Shock
Protein Family D Member-1 (HSPD1), Prostate Cancer Antigen-3 (PCA3), PSA,
Transmembrane Serine Protease 2 (TMPRSS2), ERG, Glyceraldehyde 3-Phosphate
Dehydrogenase (GAPDH), Beta-2-Microglobulin (B2M)
60 61 RT-PCR Yes 119
Prostate Cancer Antigen-3 (PCA3)↑, PSA↑ 26 70 qPCR Yes 120
Whole-Genome Gene Expression 24 25 WGS No 121
Cadherin 3↓ 4 6 WGS Yes 122
miR-100/200b↑ 70 73 qPCR Yes 123
miR-148a↑, miR-375↑ 23 215 RT-PCR Yes 124
miR-21↓ 143 23 qPCR Yes 125
Exosomal miR-2909↑, miR-615-3p↑ 10 90 qPCR Yes 126
S100A8↓, S100A9↓ 363 283 qPCR Yes 127
miR615-3p↑, hsv1-miR-H18↑, hsv2-miR-H9-5p↑, 5 14 miRNA
Microarray
Yes 128
hsa-miR-4316↑
PCA3/PSA ratio↑ 18 34 RT-PCR Yes 129
Note: ↓/↑Expression levels in PCa group compared to that of BPH group.
Abbreviations: Let-7, lethal-7 gene family, miRNA, microRNA, qPCR, quantitative polymerase chain reaction, RT-PCR, reverse transcription polymerase chain reaction,
MS-PCR, methylation specific-polymerase chain reaction, WGS, whole genome sequencing, miRNA, microRNA.
Dovepress McNally et al
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various manufacturers and these will be on the market
soon. However, there is no consensus about which of
these tests is best and it is likely that multiple biomar-
kers must be considered by clinicians as part of the
decision-making process for any given individual.
Future Perspectives
It is clear that there is a move towards the use of
multiple biomarkers in a risk prediction model, which
could include a combination of proteomic, genomic and
clinical measurements. These multivariate models
Table 4 Urine-Based Biomarkers Derived from Proteomic Techniques
Biomarkers BPH
(n)
PCa
(n)
Method All
Significant
(p<0.05)
Reference
48 Protein Groups 9 9 MS Yes 130
Glypican-1 (GPC-1)↑ 37 41 Immunoassay Yes 131
Maltose-Binding Protein (MBP)↑, Apolipoprotein A1 (APOA1)↓, Fibrinogen Alpha
Chain (FGA)↑, Fibrinogen Gamma Chain (FGG)↓, HP↓, Inter-Alpha-Trypsin
Inhibitor Heavy Chain 4 (ITIH4)↑, Serpin Family A Member 1 (SERPINA1)↓,
Transferrin↓, Transthyretin (TTR)↓
16 16 2-D DIGE, MS Yes 132
Matrix Metallopeptidase 9 (MMP-9)↓ 8 30 Gelatin Zymography Yes 133
Fibronectin↓, TP53INP2↓ 12 8 LC-MS/MS Yes 134
PSA Glycoforms 61 38 LC-MS/MS Yes 135
Saposin B↓, Inter-α-Trypsin Inhibitor Light Chain (ITIL) Fragments↑ 16 13 2DE, SS Yes 136
Beta-2-Microglobulin (B2M)↑, Pepsinogen 3↑, and Mucin 3A↑ 83 90 iTRAQ LC/LC/MS/MS Yes 137
PSA Glycoforms 32 30 LC-MS/MS Yes 138
Furan↑, 2-ethylhexanol↓, 3,5-dimethylbenzaldehyde↓, Santolin Triene↓,
2.6-dimethyl-7-octen-2-ol↓
21 29 GC-MS Yes 139
56 Intact N-glycopeptides 6 6 HILIC Yes 140
Fucα1-6/3GlcNAc PSA Glycoforms↑ 15 16 Immunoassay Yes 141
Survivin↑ 20 39 ELISA, WB Yes 142
Osteopontin↓, Prothrombin↓ Peptides 20 28 LC-MS/MS Yes 143
Engrailed-2 (EN2)↑ 76 66 ELISA Yes 144
Arginine↑, Homoserine↑, Proline↑ 50 50 LC-MS/MS Yes 145
α-Methylacyl-CoA Racemase (AMACR), Hepsin 76 66 ELISA No 146
Spermine (Spm)↑ 88 66 UPLC-MS/MS Yes 147
PSA Glycoforms 93 74 Capillary Electrophoresis Yes 148
Urinary Vesicle-Associated PSA Extraction Ratio↑ 122 85 TEM Yes 149
Sarcosine/Creatinine Ratio↑ 208 209 Sarcosine Oxidase Method Yes 150
PF4V1↓, tPSA↑, urinary CRISP3↑ 48 86 iTRAQ LC Yes 107
Ferritin-Creatinine Ratio↑ 3 3 2DE, MS, WB Yes 151
Note: ↓/↑: Expression levels in PCa group compared to that of BPH group.
Abbreviations: MS, mass spectrometry, 2D DIGE, 2-dimensional fluorescence difference gel electrophoresis, LC-MS, liquid chromatography-mass spectrometry, ELISA,
enzyme-linked immunosorbent assay, WB, Western blot, ELLA, enzyme-linked lectin assay, IHC, immunohistochemistry, iTRAQ, isobaric tag for relative and absolute
quantitation, GC-MS, gas chromatography-mass spectrometry, HILIC, hydrophilic interaction liquid chromatography, UPLC-MS, ultra-performance liquid chromatography-
mass spectrometry, TEM, transmission electron microscopy.
McNally et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Cancer Management and Research 2020:125234
 
Ca
nc
er
 M
an
ag
em
en
t a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
86
.1
29
.2
14
.4
0 
on
 2
7-
Ju
l-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
should result in a stronger degree of accuracy compared
to that of a single marker for the prediction of PCa. The
standardized use of such risk stratification is recom-
mended by the recent NICE guidelines.157 Several dif-
ferent models have been developed and are currently
employed, each demonstrating their superiority to the
use of tPSA measurement alone. The 4Kscore is
a multivariate model that is used to identify the risk of
aggressive PCa. Using a panel of 4 protein biomarkers,
combined with clinical information, such as age and
DRE results, the model achieved an AUC of 0.90 in
one trial (n=1012).158 Similarly, the Stockholm-3 risk-
based model (S3M) incorporates several plasma protein
biomarkers (PSA, free PSA, intact PSA, hK2, MSMB,
and M1C1) together with clinical data and individual
genetic information to predict the likelihood of PCa.
Using a validation cohort comprising of 47,688 men,
the S3M was estimated to reduce the number of men
biopsied by 53%, as well as avoiding 76% of negative
biopsies when compared to the standard tPSA
method.159 Other risk stratification tools include the
European Randomized Study of Screening for Prostate
Cancer (ERSPC) risk calculator, which uses PSA, DRE,
prostate volume and previous biopsy status to predict
PCa risk.160 In North America, the Prostate Cancer
Prevention Trial (PCPT) risk calculator uses PSA,
DRE, family history, previous biopsy status, age, and
race to do the same.161 Interestingly, one Irish study
which directly compared these two models concluded
the EPSRC was superior for the prediction of PCa in
an Irish population (n=2001) and advised combining it
with the PHI model to improve accuracy.162 A study by
Murphy et al in 2018 investigated a combination of data
from DNA methylation, transcripts, protein and glyco-
sylation biomarkers for use in a single PCa biomarker
panel. Using modeling techniques on almost 200 vari-
ables the authors achieved an AUC of 0.91 when differ-
entiating various stages of PCa severity from indolent to
aggressive (n=158). This article is the first to incorpo-
rate data from five omic platforms retrieved from tissue
and serum and clearly shows that the accuracy and
predictive power of PCa models come from this multi-
platform approach.163 Others have illustrated how tech-
nology can incorporate the measurements for ease of
use. The Rotterdam Prostate Cancer Risk Calculator
(RPCRC) utilizes a smartphone app with up to 11 clin-
ical parameters used in combination to predict the risk
of PCa and stratify those patients in need of a prostate
biopsy. The algorithm has been used on around 6500
patients so far with AUC 0.72–0.81 for the prediction of
PCa.164 Although there is no consensus yet about which
of these models is best, it is clear that many men
presenting with symptoms of PCa could benefit from
the use of these multivariate models to help determine
their subsequent treatment.
Together, these studies demonstrate that the use of PSA
screening can be improved to develop a more sophisticated
method for the diagnosis and risk prediction of PCa. With
such a vast majority of biomarkers being investigated, it is
unfortunate that none have found clinical utility. The
pathogenesis of PCa is complex and it is unlikely
a single biomarker will arise as a replacement to PSA.
Nonetheless, there is clear scope for further novel discov-
eries in this area, particularly in identifying new biomar-
kers that can be included in multivariate models that can
aid PSA in identifying PCa patients earlier.
There is also an emerging role in the use of exosomes
to aid in the diagnosis of PCa. Exosomes are small vesi-
cular bodies released from a whole array of cells, they
contain miRNA, mRNAs, and proteins that possess the
potential to regulate signaling pathways in cells.165
Nilsson et al described in 2009 how they showed the
presence of two known PCa biomarkers (PCA3 and
TMPRAA2:ERG) within exosomes of urine patients,
which in turn shows the potential for diagnosis and mon-
itoring of patients in cancer care.166 One review states that
exosomes have the potential of predicting the prognosis of
castration-resistant PCa, inducing PCa drug treatment sen-
sitivity as well as being used as a marker for PCa drug
response. In addition, exosomes can be used as a delivery
vector to target malignant cells, as well as being utilized in
tumor vaccination.165 However, with no gold standard in
place for exosome isolation to validate these promising
findings, it will not be possible until a uniformly defined
method of isolation and characterization is in place.167
Nevertheless, with the accumulation of evidence, exo-
somes may prove to be a valuable source of biomarker
material for informing PCa diagnosis, prognosis and ther-
apy in the very near future.
Summary
Management of PCa in primary care presents several chal-
lenges for clinicians. Current diagnosis, based primarily on
DRE and PSA measurements, can result in patients being
sent for invasive biopsies that they do not require.
A diagnostic test that can more accurately distinguish BPH
Dovepress McNally et al
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from PCawould help alleviate clinical uncertainty in primary
care, with tangible benefits for both the individual patients
and the healthcare system. The use of multivariate biomarker
measurement is required to differentiate BPH from PCa.
Combining selected biomarkers with clinical risk factors
could be used to build a robust risk stratification model that
could effectively triage patients within primary care; low and
high risk. However, this clearly depends on the identification
and validation of an optimal combination of biomarkers to
use, so continued research is required to identify the combi-
nation of biomarkers with the sensitivity and specificity to
direct clinical management.
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